{
  "retracted": false,
  "timestamp": 1424736000000,
  "updates": [
    {
      "timestamp": 1496047246290,
      "identifier": {
        "doi": "10.1212/wnl.0000000000001255"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1212/wnl.0000000000000355"
  },
  "publisher": "Ovid Technologies (Wolters Kluwer Health)",
  "title": "MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study"
}
